SARS-CoV-2 antibodies in inflammatory neurological conditions: a multicentre retrospective comparative study

It is well established that neurological and non-neurological autoimmune disorders can be triggered by viral infections. It remains unclear whether SARS-CoV-2 infection induces similar conditions and whether they show a distinctive phenotype. We retrospectively identified patients with acute inflammatory CNS conditions referred to our laboratory for antibody testing during the pandemic (March 1 to August 31, 2020). We screened SARS-COV-2 IgA/IgG in all sera by ELISA and confirmed the positivity with additional assays. Clinical and paraclinical data of SARS-COV-2-IgG seropositive patients were compared to those of seronegative cases matched for clinical phenotype, geographical zone, and timeframe. SARS-CoV-2-IgG positivity was detected in 16/339 (4%) sera, with paired CSF positivity in 3/16. 5 of these patients had atypical demyelinating disorders and 11 autoimmune encephalitis syndromes. 9/16 patients had a previous history of SARS-CoV-2 infection and 6 of them were symptomatic. In comparison with 32 consecutive seronegative controls, SARS-CoV-2-IgG-positive patients were older, frequently presented with encephalopathy, had lower rates of CSF pleocytosis and other neurological autoantibodies, and were less likely to receive immunotherapy. When SARS-CoV-2 seropositive versus seronegative cases with demyelinating disorders were compared no differences were seen. Whereas seropositive encephalitis patients less commonly showed increased CSF cells and protein, our data suggest that an antecedent symptomatic or asymptomatic SARS-CoV-2 infection can be detected in patients with autoimmune neurological conditions. These cases are rare, usually do not have specific neuroglial antibodies. Supplementary Information The online version contains supplementary material available at 10.1007/s12026-023-09384-2.


Introduction
SARS-CoV-2 primarily causes a respiratory infection, but accumulating case reports and few isolated multicentre studies have described patients with concomitant CNS disorders [1][2][3]. Indeed, a large self-controlled case study has demonstrated an increased incidence of demyelinating events, myelitis, encephalitis, and meningitis following SARS-CoV-2 positivity [4]. Most of these larger studies are observational and lack appropriate control groups. Given many neurological conditions are idiopathic, these populations carry great importance, particularly in a pandemic scenario. Despite this, systematic comparisons of patients with and without concomitant or antecedent SARS-CoV-2 infection and CNS symptoms remain unreplicated.
Herein, we assess SARS-CoV-2 seropositivity in a consecutive cohort of patients referred for neurological autoantibody testing to explore the prevalence of SARS-CoV-2-IgG positivity and ask whether clinical and paraclinical features differed between seropositive and seronegative patients with suspected CNS autoimmune disorders.

Study subjects and patients
We retrospectively identified patients referred to the Laboratory of Neuropathology, University Hospital of Verona, Italy, for testing of autoantibodies against myelin oligodendrocyte glycoprotein (MOG), aquaporin-4 (AQP4), and onconeural or neuronal cell surface antigens between March 1, 2020 and August 31, 2020. Of the 391 consecutive patient samples, we excluded 39 samples of patients with a chronic disease or referred during a relapse of a known condition and 13 patients in whom only CSF was available. From the remaining 339 cases, 232 were referred for autoantibody analyses related to demyelinating diseases and 107 to autoimmune encephalitis.

Study subjects and controls
SARS-CoV-2-IgG-positive patients were classified according to their clinical phenotype at hospital discharge into two groups: (1) "suspected autoimmune encephalitis/ encephalopathy" which included patients with autoimmune encephalitis or encephalopathy and new-onset refractory status epilepticus -NORSE; and (2) "atypical demyelinating disorders" including isolated optic neuritis, isolated myelitis, acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorder-NMOSD-, and MOG-IgG-associated disorder-MOGAD. Encephalitis, limbic encephalitis, and ADEM were defined according to diagnostic criteria [6,7]. As controls, we collected information from SARS-CoV-2 IgA/IgG seronegative patients who had a matched clinical phenotype and enrolled in the same timeframe and from the same centres of SARS-CoV-2-positive patients. The selection of seronegative cases from the same geographical area and in the same timeframe is meant to avoid any possible bias related to the presence of different SARS-CoV-2 strains. Similarly, the selection of matched clinical phenotypes is meant to avoid biases related to the inclusion of cases referred for autoantibody testing despite a low pre-test probability of being positive (i.e. multiple sclerosis in the atypical demyelinating disorders group). Lastly, clinical information from patients referred from other institutions were anonymously collected by referring physicians in an electronic spreadsheet.

Autoantibody testing
A live cell-based immunofluorescence assay was used to analyse antibodies to MOG [8], a fixed cell-based assay to detect autoantibodies against neuronal cell surface antigens and aquaporin-4, and a line blot followed by immunohistochemistry on rat cerebellum to test and confirm autoantibodies to intracellular/synaptic antigens (Euroimmun, Germany).

Statistical analysis
Differences in categorical variables were assessed with Chisquare test or Fisher Test, as appropriate. Mann-Whitney test was applied to compare median values. P value < 0.05 was considered statistically significant.

Standard protocol approvals, registrations, and patient consents
This study was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration, and its later amendments or comparable ethical standards, and was approved by the local Bioethics Committee (Comitato Etico per la Sperimentazione Clinica, Azienda Ospedaliera Universitaria Integrata di Verona; BIOB-NEU-DNA-2014, protocol 13,582).

Results
We identified SARS-CoV-2 IgA and/or IgG in 23/339 (7%) patients: IgA and IgG in 13, IgA only in 9 and IgG only in 1. After additional SARS-CoV-2 assays, 16 of 23 (16/339; 4%) patients were confirmed as seropositive cases; the remaining 7 patients with SARS-CoV-2 IgA positivity only at screening assay were excluded. From CSF testing, 4 patients were positive for SARS-CoV-2 IgG at the screening assay, with 3/4 confirmed on additional testing.
As controls, we included all (n = 32) consecutive SARS-CoV-2-IgG seronegative patients with matched clinical features who were referred from the same geographical areas in the same timeframe ( Fig. 1). Over the 6 months of study, SARS-CoV-2 IgG positivity and neurological autoantibodies showed similar rates (Fig. 2).
Clinical and paraclinical features of SARS-CoV-2-IgG seropositive patients (Table 2) revealed that only 9/16 patients reported an antecedent history of SARS-CoV-2 infection and 6 of them were symptomatic while 3 remained . Among the 5 patients with demyelinating disorders and SARS-CoV-2-IgG positivity, two patients experienced isolated optic neuritis, two transverse myelitis, and one patient had a diagnosis of ADEM. One patient with transverse myelitis and the patient with ADEM had SARS-CoV-2-IgG CSF positivity. Among 23 patients with suspected encephalitis/encephalopathy and SARS-CoV-2-IgG positivity, 3 were diagnosed with encephalopathy, 1 with NORSE, 5 fulfilled diagnostic criteria for possible autoimmune encephalitis (in one case with anti-titin antibodies in both serum and CSF), and two patients fulfilled the diagnostic criteria for seronegative limbic encephalitis. Notably, one of the two patients with limbic encephalitis had CSF SARS-CoV-2-IgG positivity.

Discussion
Herein, we describe a cohort of patients with neurological symptoms and concomitant SARS-CoV-2-IgG antibodies and compare them with clinically, geographically and time-matched SARS-CoV-2-IgG seronegative patients. We observed that (1) the rate of SARS-CoV-2-IgG positivity in patients referred for neurological autoantibody testing was 4%; (2) the rate of SARS-CoV-2 positivity was 33% in those patients who received a final diagnosis of atypical demyelinating disorders or autoimmune encephalitis/ encephalopathy; (3) neurological symptoms also occur in patients with an unknown (44%) or asymptomatic antecedent infection (33%); (4) SARS-CoV-2-IgG seropositive cases showed less frequently antibody positivity and CSF inflammatory signs, despite the more common occurrence of encephalopathy; this difference was mainly due to cases with suspected encephalitis/encephalopathy; (5) SARS-CoV-2-IgG seropositive patients with atypical demyelinating disorders do not show clinical/paraclinical peculiarities.
An association between SARS-CoV-2 infection and inflammatory neurological disorders has been postulated, particularly in relation to Guillain-Barré syndrome, but remains unproven [9]. For other autoimmune neurological conditions, such as demyelinating disorders and autoimmune encephalitis, this relationship is largely based on case reports or small, often uncontrolled case series. Hence, our study has contributed to this literature by limiting a variety of biases with a robust control group. Our data suggest that demyelinating disorders may occur during/after SARS-CoV-2 infection, in accordance with the few isolated cases with myelitis or optic neuritis previously described [10,11], and with a non-significant increase of MOG-IgG positivity in patients with positive SARS-CoV-2 IgG [12]. However, post-SARS-CoV-2 demyelinating attacks may not display a peculiar phenotype and this may relate to the pro-inflammatory cytokine milleu as a pathogenic agent which has been seen in other neurological conditions [13]. On the other hand, SARS-CoV-2-IgG-positive patients with suspected autoimmune encephalitis/encephalopathy have similar clinical features but different paraclinical findings in comparison with seronegative patients. Our results are in agreement with recent findings in terms of percentage of SARS-CoV-2-IgG seropositive cases (3 vs 4%) and negativity for neural antibodies [14]. The occurrence of encephalitis/ encephalopathy in SARS-CoV-2-IgG seropositive patients might be linked, rather than with the presence of autoantibodies, with the cytokine storm associated with SARS-CoV-2 infection, where the release of pro-inflammatory cytokines can activate inflammatory processes and dysregulate immune responses [15]. In our cohort, we found low rates of SARS-CoV-2 antibodies in CSF samples, despite the high prevalence of encephalitis/encephalopathy. These results further support a predominant role of the cytokine storm rather than directly antibodies in the development of encephalitis/ encephalopathy, as seen in patients developing Chimeric antigen receptor (CAR) T cell therapy-related toxicities [16].
Indeed, our observations are consistent with previous data reporting mostly negative antibody results in patients with encephalitis and acute SARS-CoV-2 infection and confirm None the prominent role of cytokines rather than autoantibodies in SARS-CoV-2 related encephalitis [2,14,15]. Despite its limitations in terms of retrospective design, small size and possible referral bias, our study shows that CNS involvement can occur in patients with an antecedent SARS-CoV-2 infection, regardless of respiratory and systemic involvement, and usually do not display specific clinical manifestations or neuronal antibodies positivity. These observations retain relevant diagnostic and therapeutic implications for neurological symptoms occurring during and after the COVID-19 pandemic.
Funding Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.
Data availability Data are available upon reasonable request. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.